体外展示技术及其在抗体工程中的应用

体外展示技术包括核糖体展示技术、mRNA展示技术、DNA展示技术,是在无细胞蛋白质表达体系内将基因型和表型通过一定的方法连接在一起,体外高通量的筛选多肽和蛋白质的技术。抗体的产生是一个不断选择的过程,利用体外展示技术在体外选择针对某一抗原的抗体分子,并结合基因工程技术对抗体进行改造,以产生高亲和力、高特异性的抗体。体外展示技术的研究和应用已越来越广泛,有望成为下一代的抗体制备技术。     

HIV蛋白质优势B细胞抗原表位的筛选、重组表达与抗原性鉴定

设计了一种新的病原体蛋白质B细胞抗原表位的筛选和重 组表达方法。不须使用抗原,而通过交替用病人血清IgG抗体“淘洗”(biopanning)随机肽库和用正常人血清IgG反向吸附,来获得特异抗原表位资料。用HIV病人血清的IgG抗体淘洗噬菌体递呈随机十二肽库,再以正常人IgG抗体吸附,筛选到了能和HIV病人血清发生特异反应的噬菌体克隆,经ELISA、DNA测序等,成功地筛选出了位于HIV gp41外膜蛋白、高亲和力、构型特异的优势B细胞抗原表位(602GCSGKLICTTNV613)。用大肠杆菌硫氧还蛋白作为骨架,在其活性部位以“内融合”形式重组表达了该抗原表位,纯化的重组蛋白具有良好的抗原性,能与HIV(+)IgG抗体及艾滋病人血清呈特异反应,表明本技术路线可以有 效地进行HIV蛋白质的B细胞抗原表位筛选和重组表达。此方法也可移植于其它病原微生物抗原或自身抗原的表位研究,继而为基于抗原表位水平的特异诊断试剂的研制、疫苗的设计提供依据。     

B细胞表位作图研究进展

抗原-抗体的特异性结合是由抗体表面的抗原决定簇与抗原表面的表位基序间的特异性互补识别决定的。B细胞表位作图既包括B细胞抗原表位基序的鉴定(即确定抗原分子上被B细胞表面受体或抗体特异性识别并结合的氨基酸基序),也包括绘制抗原蛋白的全部或接近全部的B细胞表位基序在其一级或高级结构上的分布图谱的过程。B细胞表位作图是研发表位疫苗、治疗性表位抗体药物和建立疾病免疫诊断方法的重要前提。目前,已经建立了多种B细胞表位鉴定或绘制抗原蛋白B细胞表位图谱的实验方法。基于抗原-单抗复合物晶体结构的X-射线晶体学分析的B细胞表位作图和基于抗原蛋白或抗原片段的突变体库筛选技术的B细胞表位作图可以在氨基酸水平,甚至原子水平上揭示抗原分子上与单抗特异性结合的关键基序;其它B细胞表位作图方法(如基于ELISA的肽库筛选技术)常常只能获得包含B细胞表位的抗原性肽段,因而,很少用于最小表位基序的鉴定;而改良的生物合成肽法多用于B细胞表位的最小基序鉴定和精细作图。鉴于每种B细胞作图方法都存在各自的优势与不足,B细胞表位作图往往需要多种作图方法的有机结合。本文对目前常用的B细胞表位作图的实验方法及其在动物疫病防控中的应用进行综述,以期为研究者设计最佳的表位作图方案提供参考。     

鼠源性抗雄性特异性抗原噬菌体Fab抗体的制备及分析

利用噬菌体抗体库筛选技术获得抗雄性特异性抗原的噬菌体Fab抗体,首次采用雄鼠脾细胞对鼠源性抗雄性特异性抗原噬菌体Fab抗体库进行3轮亲和富集和2轮雌鼠脾细胞吸附,对筛选后特异性噬菌体Fab抗体进行ELISA分析,重组率鉴定及基因测序分析。结果显示,5次筛选后的15个菌落中有9个能产生抗雄性特异性抗原特异性噬菌体抗体,噬菌体Fab抗体的基因重组率为60%,E5克隆的重链、轻链可变区序列分别属于VH1和VκⅣ基因家族,这为挑选出高亲和力的抗雄性特异性抗原噬菌体Fab抗体奠定了实验基础,将推进雄性特异性抗原及其抗体的研究进程,并为性别控制研究开创新途径。     

人源抗ICAM-1单链抗体的制备及其生物学活性鉴定

利用噬菌体展示技术筛选特异性人源抗ICAM-1单链抗体（Anti-human ICAM-1 scFv）并进行生物学活性鉴定。应用Tomlinson I+J噬菌体抗体库,以P1抗原肽为包被抗原,经过4轮“吸附-洗脱-扩增”进行亲和富集筛选。以PCR反应、ELISA抗原交叉反应和Dot blotting实验进行阳性克隆的鉴定。scFv经原核表达和分离纯化后,以Western blotting实验、竞争ELISA实验和细胞黏附抑制实验对其生物学活性进行初步鉴定。Tomlinson I+J噬菌体抗体库经4轮亲和富集筛选,利用ELISA方法成功筛出4株阳性克隆。通过PCR鉴定反应、ELISA抗原交叉反应和Dot blotting实验,最终获得了1株既能与P1抗原肽特异结合又能与人ICAM-1抗原特异结合的阳性克隆J-A1。对scFv进行原核表达和亲和层析后获得了高纯度的目的蛋白。竞争ELISA实验和细胞黏附抑制实验证实纯化的scFv具有良好的亲和活性和抗细胞黏附活性。文中成功利用噬菌体展示技术筛选到特异性人源抗ICAM-1 scFv,为进一步探索该抗体在炎症相关性疾病治疗中的应用奠定了基础。     

噬菌体展示技术及其在肿瘤研究中的应用

噬菌体表面展示技术是一项特异性多肽或蛋白的筛选技术,它将随机序列的多肽或蛋白片段与噬菌体衣壳蛋白融合表达而呈现于病毒表面,被展示的多肽能保持相对独立的空间结构,使其能够与配体作用而达到模仿性筛选特异性分子表位,从而提供了高通量高效率的筛选系统。近年来噬菌体展示技术已广泛应用于肿瘤抗原抗体库的建立、单克隆抗体制备、多肽筛选、疫苗研制、肿瘤相关抗原筛选和抗原表位研究、药物设计、癌症检测和诊断、基因治疗及细胞信号转导研究等。就近年来噬菌体展示技术在肿瘤相关研究中的运用作以综述。     

噬菌体显示技术用于抗体表位的筛选

利用噬菌体随机肽库筛选抗TNF单抗表位的研究中,就抗体的选择、肽库富集的检测、筛选得到的表位多肽的验证及如何提高筛选的成功率等,进行了一些初步探索. 实验结果表明,由识别线性抗原位点的抗体较容易筛选到噬菌体呈现表位,具有较强中和活性的抗体,因多识别空间构型抗原位点而增加筛选难度. NC膜斑点印迹、ELISA及DNA测序均可作为筛选富集的检测方法. 用与天然抗原同源比较的方法及竞争性ELISA分析,可以帮助确定噬菌体呈现多肽是否是抗体表位.     

EGFRvⅢ胞外区基因重组腺病毒的构建及单域抗体的制备北大核心CSCD

本研究旨在构建能够表达人表皮生长因子EGFRvⅢ胞外区基因的重组腺病毒,并通过免疫骆驼构建噬菌体单域抗体库,筛选和制备EGFRvⅢ胞外区特异性单域抗体并对其进行鉴定。从人前列腺癌细胞系PC-3细胞中提取总RNA,反转录为cDNA,以cDNA为模板扩增EGFRvⅢ胞外区基因,并连接pAdTrack-CMV质粒载体,转化含有pAdEasy-1的大肠杆菌(Escherichia coli)BJ5183感受态细胞,获得同源重组质粒转染HEK293A细胞,得到表达EGFRvⅢ胞外区蛋白的重组腺病毒。利用重组腺病毒免疫双峰驼,构建EGFRvⅢ胞外区特异性噬菌体单域抗体库,并以EGFRvⅢ蛋白为筛选抗原,对其进行筛选,对筛选得到的单域抗体进行诱导表达、纯化及鉴定。结果表明获得了表达EGFRvⅢ胞外区基因的重组腺病毒。构建得到的EGFRvⅢ特异性噬菌体单域抗体库的库容为1.4×109;经过3轮富集和筛选,通过噬菌体ELISA筛选出31个与EGFRvⅢ胞外区蛋白结合的阳性克隆,并对OD450值较高的重组单域抗体E14进行了表达和纯化。经ELISA鉴定,重组单域抗体E14可与EGFRvⅢ胞外区蛋白产生抗原抗体结合反应,具有较高的亲和力。说明制备的EGFRvⅢ特异性噬菌体单域抗体库具有较高的库容和多样性,且筛选得到的单域抗体具有较高的抗原活性和免疫学反应性,为今后以EGFRvⅢ为靶点的恶性肿瘤的诊断和治疗提供新的实验依据。     

抗体库技术与策略进展

抗体库为基因工程抗体领域带来了革命性的突破,其技术核心是将抗体的表型与基因型偶联,从抗体库中找到针对特异抗原的抗体基因。抗体库的基因可来自免疫或非免疫的策略;抗体分子形式包括Fab、单链抗体、单域抗体、微型抗体、最小识别单位等;展示平台包括噬菌体、核糖体、酵母、细菌、杆状病毒、哺乳细胞等;筛选策略包括抗原、细胞、组织切片、体内筛选等。抗体库在操作上具有高通量、工程化的特点,便于实现产业化,显示出巨大的商业开发价值。     

噬菌体抗体库筛选技术研究进展

噬菌体抗体库技术是一项新兴的基因工程抗体技术,应用这项技术获得高特异性抗体的关键之一就是筛选环节。根据抗原性质以及筛选目的的不同,筛选方法的选择也不相同,各种筛选策略的优化对中和抗体的获得有至关重要的作用。     

基于细胞的抗单增李斯特菌单域重链抗体的筛选及鉴定

【目的】获得针对单增李斯特菌的特异性单域重链抗体,并对筛选过程中特异性克隆的富集规律进行分析,为筛选具有种属特异性的噬菌体展示抗体提供参考。【方法】采用固相筛选技术,以热灭活的单增李斯特菌菌体为抗原,通过四轮常规筛选和一轮消减筛选,从驼源天然噬菌体展示文库中筛选针对单增李斯特菌的单域重链抗体。采用Phage-ELISA法,对后四轮筛选洗脱物中随机挑选的噬菌体进行鉴定,阳性克隆进行基因测序及结合特异性分析。通过多序列比对分析将获得的基因序列进行分组和统计。【结果】成功筛选到2株单增李斯特菌特异性的单域重链抗体。【结论】在优化的筛选条件下,基于全细胞的筛选方法能够获得特异性识别单增李斯特菌的单域重链抗体,消减筛选对于去除非特异性克隆是有效的和必要的。     

Effective use of nitrocellulose-blotted antigens for phage display monoclonal antibody selection

The combinatorial phage display library approach to antibody repertoire cloning offers a powerful tool for the isolation of specific antibodies to defined target antigens. Panning strategy is often a very critical point for selecting antibody displayed on the surface of bacteriophages. Most selection strategies described to date have relied on the availability of purified and often recombinant antigen, providing the possibility to perform selections on a well defined antigen source. However, when the antigen is difficult to purify by means of laborious and time-consuming chromatography procedures, panning of phage antibody libraries has to be performed on complex antigen sources such as cell surfaces or tissue sections, or even by in vivo selection methods. This provides a series of technical and experimental complications. In the present work, we successfully generated a mouse monoclonal antibody fragment from a phage display library directed against protein E7 of HPV18 avoiding antigen purification as for immunizing mice as for antibody library selection. Our work demonstrates the feasibility of phage antibody selections on antigens transferred to a nitrocellulose membrane as solid support, using one-dimensional polyacrylamide gel electrophoresis system as the only practice to separate a given antigen present in bacterial crude cell lysate.     

Production of human single-chain fragment antibody (ScFv) against human epidermal growth factor receptor-2 (HER-2) by phage display technology

Breast cancer with more than 1.7 million diagnoses per year has been known as one of the most prevalent cancers among women worldwide. Despite the availability of advanced treatment options, cancer progression and metastasis is observed in 20% of patients. Human epidermal growth factor receptor-2 (HER-2) is considered as an important prognostic and diagnostic tumor marker for breast cancer. While HER-2 is expressed on the surface of normal cells, its overexpression occurs in 20–25% on breast cancer tumor cells. This type of tumor which is referred to as HER-2+ is the most aggressive type of breast cancer and shows more resistance to radiotherapy. Single-chain fragment antibodies (ScFvs) offer several advantages in comparison to conventional whole antibodies due to their small size. Particularly, ScFv fragments show improved diffusion and solid tumor penetration. In this study, a human ScFv antibody library was used to isolate anti-HER-2 ScFv antibodies through cell panning and mix antigen-cell panning strategies. Analysis of the binding activity and specificity of isolated ScFv antibodies against HER-2-expressing cell lines and recombinant HER-2 antigen indicated the higher efficiency of the cell panning strategy in isolation of ScFv antibody fragments.     

Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library.

To generate antibodies to defined cell-surface antigens, we used a large phage antibody fragment library to select on cell transfectants expressing one of three chosen receptors. First, in vitro panning procedures and phage antibody screening ELISAs were developed using whole live cells stably expressing the antigen of interest. When these methodologies were applied to Chinese hamster ovary (CHO) cells expressing one of the receptors for a neuropeptide, somatostatin, using either direct cell panning or a strategy of depletion or ligand-directed elution, many different pan-CHO-cell binders were selected, but none was receptor specific. However, when using direct panning on CHO-cells expressing the human membrane protein CD36, an extraordinary high frequency of antigen-specific phage antibodies was found. Panning on myoblasts expressing the rat homologue of CD36 revealed a similar selection dominance for anti-(CD36). Binding of all selected 20 different anti-(CD36) phage was surprisingly inhibited by one anti-(CD36) mAb CLB-IVC7, which recognizes a functional epitope that is also immunodominant in vivo. Similar inhibition was found for seven anti-(rat) CD36 that cross-reacted with human CD36. Our results show that, although cells can be used as antigen carriers to select and screen phage antibodies, the nature of the antigen target has a profound effect on the outcome of the selection.     

A Novel Strategy for Proteome-wide Ligand Screening Using Cross-linked Phage Matrices

To find a suitable ligand from a complex antigen system is still a mission to be accomplished. Here we have explored a novel “library against proteome” panning strategy for ligand screening and antigen purification from a complex system using phage-displayed antibody technology. Human plasma proteome was targeted for phage library panning. During the process, the panning was carried out in solution, using a biotin/streptavidin beads separation system, for three rounds. Nine monoclonal phages, bound tightly to a number of unknown plasma proteins, were selected from the last round, six of which were directly employed as cross-linked matrices to purify their corresponding antigens from the plasma. The proteins isolated by G5 and E1 matrices were identified as amyloid protein and apolipoprotein A-I precursor, respectively. The results demonstrated that it was feasible to simultaneously obtain a number of ligand phages for various antigens, including low abundant proteins in a non-comparative proteome-wide system.     

从构建的噬菌体抗体库中筛选抗甲肝人单抗

用固相化甲肝抗原,对所构建的噬菌体抗体库进行了3轮淘筛。第3轮淘筛后洗脱下来的噬菌体,较第l轮增加了近100倍。含有抗体重链基因和轻链基因的重组克隆．也由淘筛前的25％增至100％。说明甲肝抗原对抗体库的淘筛,富集了表面呈现甲肝人单抗的噬菌体。经夹心ELISA法筛选到抗甲肝病毒噬菌体抗体,并以竞争抑制实验进一步证实了这些抗体的特异性。     

Tumor cell killing by in vitro affinity-matured recombinant human monoclonal antibodies

We have developed a method that allows the rapid improvement of the affinity of phage-displayed antibody fragments by selection on intact eukaryotic cells. A single chain Fv fragment, specific for the tumor-associated Ep-Cam molecule, was mutagenized by shuffling of the immunoglobulin light chain variable region and DNA shuffling of both heavy and light chain variable regions. Higher-affinity mutants were selected from small phage display libraries by cell panning under stringent conditions. When converted to an intact fully human antibody, the mutagenized anti-tumor monoclonal antibody displayed an affinity of 0.4 nM, a 15-fold improvement over the affinity of the original antibody. Compared to previously reported affinity maturation schemes, panning on intact cells does not require purified targets for selection and may be particularly useful when the target molecule can not be expressed as a recombinant molecule or easily purified without disrupting its native configuration. In vitro tumor cell killing assays demonstrated an improved performance of the higher-affinity antibody in complement-mediated tumor cell killing. In contrast, the lower-affinity antibody performed somewhat better in antibody-dependent cellular cytotoxicity assays and penetrated better in multicell spheroids of tumor cells, an in vitro model for the tumor penetration capacity of antibodies. Received: 26 February 2000 / Accepted: 26 January 2001     

Idiotype regulation of the anti-bovine serum albumin response. I. Generation of an idiotype-specific Lyt-1-2+ suppressor T cell

A monoclonal antibody (3C-7) specific for a determinant localized on the carboxy-terminus of the BSA molecule (P505-582) has been shown to cause suppression of the multispecific BSA antibody response if given i.v. before immunization. The fine binding specificity and the isotype subclass are not responsible for the suppression generated. Administration of 3C-7 i.v. results in the generation of a suppressor T cell that, when transferred into reconstituted irradiated mice, results in a diminished anti-BSA response. Suppression can be eliminated by panning T cells on idiotype (3C-7) coated plates, but not by panning on BSA, polyclonal anti-BSA antibodies, or MOPC 21. The action of the cell is antigen (BSA) specific. Idiotype-binding T cells reconstitute suppression and appear to be Lyt-1-2+. These observations demonstrate that a limited set of monoclonal antibodies directed against a single determinant on a protein molecule have the capacity to regulate the immune response to a multiplicity of determinants present on the same protein. These data support the concept of antibody-induced regulation by the induction of suppressor cells through idiotype recognition.     

A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents

Proteomics research has delivered many novel tumor targets. However, due to key limitations, it does not specifically identify targets that are most accessible for drug delivery, such as cell-surface antigens. A novel tumor antigen discovery platform based on screening a single domain antibody (sdAb) library against tumor cells and subsequently identifying the corresponding antigens of the isolated antibodies is described. An sdAb, AFAI, specific for non-small cell lung carcinoma (A549 cell line) was isolated from a phage library derived from the heavy chain antibody repertoire of a llama. The homopentamerization property of a non-toxic verotoxin B-subunit was exploited to make the ES1 pentabody, a pentameric form of AFAI. Pentamerization improved the binding of the AFAI to A549 cells dramatically and greatly facilitated antigen identification by a Western blotting/mass spectrometry approach. The antigen of ES1, which is present only in the hydrophobic, not in the hydrophilic, fraction of A549 cellular proteins, was identified as carcinoembryonic antigen-related cell adhesion molecule 6 (CEA6). CEA6 was observed to be acidic and highly glycosylated, and to exist in multiple glycoforms. The results show that the platform described here should find wide application in antigen discovery, and demonstrated that the pentabodies are very useful immunological reagents for proteomics.